SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Macdonald RL. Mechanisms of action. In: LevyRH, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia : Lippincott Williams & Wilkins, 2002: 86772.
  • 2
    Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12: 217.DOI: 10.1016/0920-1211(92)90087-A
  • 3
    Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413: 1858.DOI: 10.1016/0006-8993(87)90168-5
  • 4
    Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998;124: 127785.
  • 5
    Zhu W, Rogawski MA. Zonisamide depresses excitatory synaptic transmission by a presynaptic action [Abstract]. Epilepsia 1999;40(suppl 7):245.
  • 6
    Kawai M, Hiramatsu M, Endo A, et al. Effect of zonisamide on the release of aspartic acid and gamma-aminobutyric acid from the hippocampal slices of E1 mice. Neurosciences 1994;20: 1159.
  • 7
    Jain KK. An assessment of zonisamide as an anti-epileptic drug. Expert Opin Pharmacother 2000;1: 124560.
  • 8
    Seino M, Fujitani B. Clinical efficacy and use in epilepsy. In: LevyRH et al., eds. Antiepileptic drugs. 5th ed. Philadelphia : Lippincott Williams & Wilkins, 2002: 885.
  • 9
    Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15: 6773.DOI: 10.1016/0920-1211(93)90011-U
  • 10
    Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45: 610.DOI: 10.1111/j.0013-9580.2004.11403.x
  • 11
    Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57: 17749.
  • 12
    Commission on the Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22: 489501.
  • 13
    Hollander M, Wolfe DA. Nonparametric statistical methods. 1st ed. New York : Wiley, 1973.
  • 14
    Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313: 116974.
  • 15
    Peeters K, Adriaenssen I, Wapenaar R, et al. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003;108: 915.DOI: 10.1034/j.1600-0404.2003.00113.x
  • 16
    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55: 23642.
  • 17
    Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12: 41343.DOI: 10.1016/S1059-1311(03)00047-5
  • 18
    Oguni H, Hayashi K, Fukuyama Y, et al. Phase III clinical study of the new antiepileptic drug, AD-810 (zonisamide), in patients with childhood epilepsy. Jpn J Pediatr 1988;42: 43950.
  • 19
    Valeriano J, Lane C. Efficacy and tolerability of zonisamide in generalized seizures [Abstract]. Epilepsia 2001;42(suppl 7):188.
  • 20
    Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38: 10358.
  • 21
    Kishi T, Nejihashi Y, Kajiyama M, et al. Successful zonisamide treatment for infants with hypsarrhythmia. Pediatr Neurol 2000;23: 2747.DOI: 10.1016/S0887-8994(00)00183-1
  • 22
    Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29: 10914.DOI: 10.1016/S0920-1211(97)00069-7
  • 23
    Vossler DG and the Zonisamide PME Study Group. Multicenter, open-label, safety and efficacy study of zonisamide in patients with progressive myoclonic epilepsy [Abstract]. Neurology 2002;58(suppl 3):A2967.
  • 24
    Ganguly G, Selco S, Ko DY. Zonisamide is effective in the treatment of myoclonus status epilepticus and myoclonus in Jakob-Creutzfeldt disease [Abstract]. Epilepsia 2002;43(suppl 7):218.
  • 25
    Bourgeois BFD. Zonisamide (ZNS) in the treatment of myoclonic astatic epilepsy (MAE, Doose syndrome) [Abstract]. Epilepsia 2002;43(suppl 7):56.DOI: 10.1046/j.1528-1157.43.s.9.13.x
  • 26
    Hershkowitz L. Zonisamide therapy in patients with absence seizures [Abstract]. Epilepsia 2002;43:(suppl 7):193.DOI: 10.1046/j.1528-1157.2002.20901.x
  • 27
    Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepilepsy agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998;38: 16671.
  • 28
    Mather GG, Shah J. Drug interactions. In: LevyRH et al., eds. Antiepileptic drugs. 5th ed. Philadelphia : Lippincott Williams & Wilkins, 2002: 880.
  • 29
    Rosenfeld WE, Bergen D, Garnett W, et al. Steady-state drug interaction study of zonisamide and carbamazepine in patients with epilepsy [Abstract]. Neurology 2001;56(suppl 3):A336.
  • 30
    Levy RH, Ragueneau-Majlessi I, Garnett WR, et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol 2004;44: 12304.DOI: 10.1177/0091270004268045
  • 31
    Smith D, Brodie M, Dunkley D, et al. Steady-state drug interaction study of zonisamide and sodium valproate in epileptic patients [Abstract]. Neurology 2001;56(suppl 3):A338.
  • 32
    Brodie M, Wilson E, Smith D, et al. Steady-state drug interaction study of zonisamide and lamotrigine in epileptic patients [Abstract]. Neurology 2001;56(suppl 3):A337.